Drug Profile
VM 100
Alternative Names: VM100Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Vision Medicines
- Class Eye disorder therapies; Monoclonal antibodies; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (IV)
- 09 Nov 2015 Phase-I clinical trials in Age-related macular degeneration in USA (IV)
- 09 Nov 2015 Safety data from two phase I trial in Age-related macular degeneration released by Vision Medicines